Losses narrow at MediGene but still no deal for EndoTAG-1
This article was originally published in Scrip
Executive Summary
MediGene reported a reduced net loss for 2009, from around €31 million to €22 million, on unchanged revenues of about $40 million. The German biotech company is still waiting to sign a much-needed partnership for its lead development candidate EndoTAG-1 but it hopes to increase revenue for 2010 through product sales alone.